Cover Image
Read Now

Glatiramer acetate and interferon beta 1a and 1b for clinically isolated syndrome a review of clinical effectiveness and guidelines

This review aims to summarize and evaluate evidence regarding the clinical effectiveness and safety of glatiramer acetate, IFN beta-1a, and IFN beta-1b, in treating patients with clinically isolated syndrome (CIS). The review also aims to summarize and assess relevant evidence-based guidelines

Bibliographic Details
Main Authors: Williams, D., Butcher, Robyn (Author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health September 18, 2019, 2019
Edition:Version: 1.0
Series:CADTH rapid response report: summary with critical appraisal
Subjects:
Canada
Interferon Beta-1b / Therapeutic Use
Glatiramer Acetate / Therapeutic Use
Interferon Beta-1a / Therapeutic Use
Treatment Outcome
Practice Guidelines As Topic
Demyelinating Diseases / Drug Therapy
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:This review aims to summarize and evaluate evidence regarding the clinical effectiveness and safety of glatiramer acetate, IFN beta-1a, and IFN beta-1b, in treating patients with clinically isolated syndrome (CIS). The review also aims to summarize and assess relevant evidence-based guidelines
Physical Description:1 PDF file (32 pages) illustrations

Similar Items